Skip to search formSkip to main contentSkip to account menu

Trabedersen

A transforming growth factor (TGF)-beta2 specific phosphorothioate antisense oligodeoxynucleotide with the sequence 5'-CGGCATGTCTATTTTGTA-3', with… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antineoplastic AgentsOligodeoxyribonucleotidesThionucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Therapeutic potential of targeting Transforming growth factor beta in colorectal cancer: Rational and Progress.
BACKGROUND Colorectal cancer (CRC) is one of the most common types of cancer and is associated with an increasing rate of… 
2018
2018
Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al.
  • 2018
  • Corpus ID: 205269006
2017
2017
Correlation of circulating IL-8 levels with improved overall survival in advanced pancreatic cancer patients in response to antisense OT-101 (trabedersen) therapy.
444Background: Overexpression of the transforming growth factor-beta 2 (TGF-β2) has been suggested as a pivotal factor for… 
2016
2016
OT-101: An anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies.
e15727Background: Overexpression of transforming growth factor-beta 2 (TGF-b2) is associated with poor prognosis and plays a key… 
2012
2012
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current… 
2012
2012
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Despite the enormous advances in clinical research in oncology, the prognosis of pancreatic carcinoma remains poor. The… 
2010
2010
Trabedersen (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.
2611 Background: Trabedersen (AP 12009) is a TGF-β2-specific antisense oligonucleotide. In a randomized and active-controlled… 
2010
2010
Pseudoprogression after treatment with the TGF-beta 2 inhibitor trabedersen in high-grade glioma patients.
2054 Background: Pseudoprogression (psPD) has frequently been described in high-grade glioma (HGG) patients after… 
Review
2009
Review
2009
Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides
Antisense oligodeoxynucleotides (AS-ODNs) have been widely used to determine gene function, validate drug targets and as novel… 
2009
2009
Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma.
4619 Background: TGF-beta 2 is one of the most potent immunosuppressors and mediates escape from immunosurveillance. It also… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)